ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019
August 28 2019 - 07:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci,
Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial
Officer, will attend Citi’s investor conference on Wednesday,
September 4, 2019 at the Four Seasons Hotel in Boston, MA.
In addition, Dr. Marc Schegerin will participate in the hosted
panel discussion: Focusing the Laser on Precision Oncology, at 3:00
PM. The live webcast of the presentation will be available via the
“Investors & Media” section of ArQule’s website,
www.arqule.com, under “Events & Presentations.” A replay of the
webcast will be available shortly after the conclusion of the
presentation.
About ArQule ArQule is a biopharmaceutical company
engaged in the research and development of targeted therapeutics to
treat cancers and rare diseases. ArQule’s mission is to discover,
develop and commercialize novel small molecule drugs in areas of
high unmet need that will dramatically extend and improve the lives
of our patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, in a planned registrational trial with
cohorts in Proteus syndrome and PROS to initiate in 2019; ARQ 751,
a next generation highly potent and selective AKT inhibitor, in
phase 1 for patients with AKT1 and PI3K mutations; and
derazantinib, a multi-kinase inhibitor designed to preferentially
inhibit the fibroblast growth factor receptor (FGFR) family, in a
registrational trial for iCCA in collaboration with Basilea and
Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors,
leveraging the Company’s proprietary library of compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190828005053/en/
Corporate Contact: Kathleen Farren Investor Relations
& Executive Assistant to the CFO ir@arqule.com
Media Contact: Cait Williamson, Ph.D. LifeSci Public
Relations (646) 751-4366 cait@lifescipublicrelations.com
www.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Feb 2024 to Mar 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Mar 2023 to Mar 2024